Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses

Gerwin D Rodenburg, Elske J M van Gils, Reinier H Veenhoven, Nienke Jones, Irina Tcherniaeva, Eelko Hak, Loek van Alphen, Guy A M Berbers, Elisabeth A M Sanders

    Research output: Contribution to journalArticleAcademicpeer-review

    16 Citations (Scopus)
    239 Downloads (Pure)

    Abstract

    In this cohort study we compared IgG antibody levels between infants immunized with 7-valent CRM197-conjugated pneumococcal vaccine (PCV-7) at 2,4 and 11 months and at 2, 3, 4 and 11 months of age,as measured by double adsorption ELISA. Pre- and post-booster levels following the 2 + 1 - and 3 + 1-dose schedule were comparable for 5 out of 7 serotypes except for serotypes 6B and 19F. The proportion of children reaching post-booster antibody thresholds were comparable except for 6B (>= 1.0 mu g/ml and >= 5.0 mu g/ml) and 19F (>= 5.0 mu g/ml). Surveillance studies are warranted for vaccine impact on 6B and 19F disease cases after reduced-dose PCV-7 schedules. (C) 2009 Elsevier Ltd. All rights reserved.

    Original languageEnglish
    Pages (from-to)1391-1396
    Number of pages6
    JournalVaccine
    Volume28
    Issue number5
    DOIs
    Publication statusPublished - 3-Feb-2010

    Keywords

    • Pneumococcal conjugate vaccine
    • Immunogenicity
    • Reduced-dose schedules
    • STREPTOCOCCUS-PNEUMONIAE
    • NASOPHARYNGEAL CARRIAGE
    • LONGITUDINAL HOUSEHOLD
    • OTITIS-MEDIA
    • IMMUNOGENICITY
    • CHILDREN
    • DISEASE
    • SAFETY
    • IMMUNIZATION
    • PROTECTION

    Cite this